Results 91 to 100 of about 3,549 (185)

Structural similarity, characterization of Poly Ethylene Glycol linkage and identification of product related variants in biosimilar pegfilgrastim - Fig 7

, 2019
(A) TIC overlay of pegfilgrastim main peak and Pre-peak impurity (RRT 0.84) in peptide mapping (10–75 min) (B) TIC overlay of pegfilgrastim main peak and Pre-peak impurity (RRT 0.84) in peptide mapping (75–145 min).
Arabhi Pushpaja (6453974), Sandeep Sonar (6453956), Manish Kumar (50435), Sridevi Khambhampaty (6453983), Akash Patel (128728), Namrata More (6453959), Bhargav Prasad Kodaganti (6453968), Poonam Kapoor (6453947), Sankaranarayanan Srinivasan (116202), Suvaskumar Patel (6453950), Milan Vachhani (6453965), Jatin Patel (3415787), Upasana Choavatiya (6453971), Rakesh Shekhawat (6453941), Nidhi Nuwal (6453980), Sharwan Kumar (6453953), Manasvi Joshi (6453962), Shubhangi Argade (6453977), Chintan Kumar Shah (6453944)   +18 more
core   +1 more source

An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer

Cancer Medicine, 2018
This randomized, open‐label, active‐controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long‐acting myeloid growth factor, versus pegfilgrastim in breast cancer patients being treated with docetaxel ...
Jeffrey L. Vacirca, Arlene Chan, Klára Mezei, Clarence S. Adoo, Zsuzsanna Pápai, Kimberly McGregor, Meena Okera, Zsolt Horváth, László Landherr, Jerzy Hanslik, Steven J. Hager, Emad N. Ibrahim, Makharadze Rostom, Gajanan Bhat, Mi Rim Choi, Guru Reddy, Karen L. Tedesco, Richy Agajanian, István Láng, Lee S. Schwartzberg   +19 more
doaj   +1 more source

Cost-Effectiveness of Pegfilgrastim versus Six Days of Filgrastim for Preventing Febrile Neutropenia in Breast Cancer Patients

, 2009
Aims and background Febrile neutropenia (FN) is a major complication of chemotherapy and is associated with substantial morbidity, mortality and costs. The aim of this study was to evaluate the cost-effectiveness of primary prophylaxis with pegfilgrastim
Marco Danova, Giovanni Rosti, Quan V Doan, Silvia Chiroli   +3 more
core   +1 more source

Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management

, 2017
Objective: To review the incidence, risk factors, and management of pegfilgrastim-induced bone pain (PIBP). Data Sources: PubMed was searched from 1980 to March 31, 2017, using the terms pegfilgrastim and bone pain.
Donald C. Moore, Annie E. Pellegrino
core   +1 more source

Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. [PDF]

, 2006
peer reviewedIn order to assess the effect of Pegfilgrastim on the duration of neutropenia and clinical outcome of patients after autologous peripheral blood stem cell (PBSC) transplantation, we compared 20 consecutive patients with lymphoma or multiple ...
Frere, Pascale, Ngirabacu, Marie-Christine, Beguin, Yves, Fillet, Georges, Vanstraelen, Gaetan, Willems, Evelyne   +5 more
core   +1 more source

Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy

, 2008
ObjectivesNeutropenia and its complications, including febrile neutropenia (FN), are a common side effect of cancer chemotherapy. Results of clinical trials showed that prophylactic use of granulocyte colony-stimulating factors (G-CSF) is effective in ...
Lyman, Gary H., Cosler, Leon E., Eldar-Lissai, Adi, Culakova, Eva   +3 more
core   +1 more source

Supplementary Figure 1 from Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies

, 2016
The tumor growth inhibition (TGI) measured on day 56 confirmed the potentiation of trastuzumab antitumor activity when co-injected with pegfilgrastim. Co-treatment with pegfilgrastim and trastuzumab significantly decreased A549 growth when compared to ...
Sébastien Cornet (15070426), Olivier Trédan (736139), Anne Evesque (15070429), Eva-Laure Matera (1648159), Doriane Mathé (783662), Kamel Chettab (783660), Charles Dumontet (193436)   +6 more
core   +1 more source

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors

, 2015
Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long ...
Lambertini, Matteo, Lambertini M, Del Mastro L, Del Mastro, Lucia, Pronzato, Paolo, Ferreira AR, Ferreira, Arlindo R, Danesi R, Pronzato P, DANESI, ROMANO, Ferreira, Arlindo   +10 more
core   +1 more source

Role of biosimilar pegfilgrastim in the treatment of febrile neutropenia: A Mini Review

7-15Biologics have no true generics due to their complex nature but biosimilars offer a hopeful alternative. Biosimilars are similar to biologics as tested with comparable safety and efficacy profiles to the reference product.
S, Ahmad, Shahab, Shania
core   +1 more source

Biological effects of pegfilgrastim on circulating neutrophils in breast cancer patients undergoing dose-dense chemotherapy.

, 2008
Pegfilgrastim is a covalent conjugate of filgrastim and polyethylene glycol that has proved to be effective in supporting myelopoiesis during chemotherapy.
Benatti C, Danova M, Collovà E, Manzoni M, Travaglino E, INVERNIZZI, ROSANGELA, RICCARDI, ALBERTO, GRASSO, DONATELLA, Livraghi L   +8 more
core   +1 more source